Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: Mechanism and therapeutic potential

International Journal of Cancer

Volumn 124, Issue 2, 2009, Pages 473-482

  Longe, Harold O ^a,b   Romesser, Paul B ^a   Rankin, Andrew M ^a   Faller, Douglas V ^a   Eller, Mark S ^a   Gilchrest, Barbara A ^a   Denis, Gerald V ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cancer therapy; Lymphoma; Oligonucleotide; Telomere

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; OLIGONUCLEOTIDE; PREDNISONE; PROTEIN P53; TELOMERE HOMOLOG OLIGONUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; CASPASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T CELL LYMPHOMA; ANIMAL; CHEMISTRY; LYMPHOCYTE; LYMPHOMA; MAXIMUM TOLERATED DOSE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TELOMERE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA; MAXIMUM TOLERATED DOSE; MICE; OLIGONUCLEOTIDES; PHOSPHORYLATION; TELOMERE;

EID: 58249084335     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23946     Document Type: Article

References (36)

1. Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrest BA. Induction of apoptosis by telomere 3′ overhang-specific DNA. Exp Cell Res 2002;276:185-93.
2. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA. Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc Natl Acad Sci USA 2003;100:527-31.
3. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrest BA. Telo-mere-based DNA damage responses: a new approach to melanoma. FASEB J 2004;18:1373-81.
4. Kelland L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 2007;13:4960-3.
5. Li GZ, Eller MS, Hanna K, Gilchrest BA. Signaling pathway requirements for induction of senescence by telomere homolog oligonucleo- tides. Exp Cell Res 2004;301:189-200.
6. Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrest BA, Kondo S. Telomere 3′ overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J 2007;21:2918-30.
7. Eller MS, Li GZ, Firoozabadi R, Puri N, Gilchrest BA. Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3′ overhang specific DNA. FASEB J 2003;17:152-62.
8. Goukassian DA, Helms E, van Steeg H, van Oostrom C, Bhawan J, Gilchrest BA. Topical DNA oligonucleotide therapy reduces UV-induced mutations and photocarcinogenesis in hairless mice. Proc Natl Acad Sci U S A 2004;101:3933-8.
9. Hadshiew IM, Eller MS, Gasparro FP, Gilchrest BA. Stimulation of melanogenesis by DNA oligonucleotides: effect of size, sequence and 5′ phosphorylation. J Dermatol Sci 2001;25:127-38.
10. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 1996;15:1734-41.
11. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
12. Eller MS, Liao X, Liu S, Hanna K, Bäckvall H, Opresko PL, Bohr VA, Gilchrest BA. A role for WRN in telomere-based DNA damage responses. Proc Natl Acad Sci U S A 2006;10:15073-8.
13. Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, Gilchr-est BA. Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res 2007;9:R13.
14. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999;283:1321-5.
15. Cao Z, Huang CC, Tan W. Nuclease resistance of telomere-like oligo-nucleotides monitored in live cells by fluorescence anisotropy imaging. Anal Chem 2006;78:1478-84.
16. Ohashi N, Yaar M, Eller MS, Truzzi F, Gilchrest BA. Features that determine telomere homolog oligonucleotide-induced therapeutic DNA damage-like responses in cancer cells. J Cell Physiol 2007; 210:582-95.
17. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965;18:522-9.
18. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972;49:891-5.
19. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phor-bol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 1990;82:501-9.
20. Gabay C, Ben-Bassat H, Schlesinger M, Laskov R. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Haematol 1999;63:180-91.
21. Greenwald R, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, Faller DV, Denis GV. μE-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004;103:1475-84.
22. Lenburg M, Sinha A, Faller DV, Denis GV. Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem 2007;282:4803-11.
23. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000;6:4950-6.
24. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smoro-dinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphoryl-ation of p53 by ATM in response to DNA damage. Science 1998; 281:1674-7.
25. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11:3471-81.
26. Su TT, Rawlings DJ. Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 2002;168:2101-10.
27. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, Daniel PT. Activation of caspase-8 in drug-induced apopto-sis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001;97:1378-87.
28. Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, Giaccone G. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000;6:203-12.
29. Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005;4:7-14.
30. Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI; Southwest Oncology Group. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, adriamycin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21:2466-73.
31. Gilchrest BA, Eller MS. The tale of the telomere: implications for prevention and treatment of skin cancers. J Investig Dermatol Symp Proc 2005;10:124-30.
32. Weng NP. Telomere and adaptive immunity. Mech Ageing Dev 2008;129:60-6.
33. Opresko PL, Otterlei M, Graakjaer J, Bruheim P, Dawut L, Kølvraa S, May A, Seidman MM, Bohr VA. The Werner syndrome helicase and exonuclease cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2. Mol Cell 2004;14:763-74.
34. Zhou JM, Zhu XF, Lu YJ, Deng R, Huang ZS, Mei YP, Wang Y, Huang WL, Liu ZC, Gu LQ, Zeng YX. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene 2006;25:503-11.
35. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol 2003;170:73-83.
36. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracel-lular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007;81:15-27.